Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone + R-ICE in Relapsed/Refractory Aggressive NHL
NCT03458260Phase 2Completed
- Sponsor
- LYSARC
- Start
- Dec 2018
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 2 trial of pixantrone in non-Hodgkin lymphoma (NHL), sponsored by LYSARC. Started Dec 2018; status: completed.
02
Drugs
pixantrone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03458260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458260.